Protalix Biotherapeutics, Inc. Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium

CARMIEL, Israel, Feb. 9, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE AMEX:PLX) (TASE:PLX), announced today that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2012 being held February 8-10 in San Diego, California. Taliglucerase alfa is the Company's proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), which is being developed for the treatment of Gaucher disease.